{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:38:10Z","timestamp":1792269490921,"version":"4.4.0"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Neuroretinitis is a very rare but recognized immune-related adverse event (irAE) of immune checkpoint inhibitor (ICI) therapy. We present a case of likely ICI-associated neuroretinitis following combination nivolumab and ipilimumab treatment for stage IIIC cutaneous melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Our patient is a 48-year-old woman with stage IIIC melanoma who developed acute left eye vision loss approximately three months after initiating nivolumab and ipilimumab, near the end of a corticosteroid taper for a concurrent systemic irAE. Examination showed best-corrected visual acuity of 20\/400, severely reduced color vision (2\/14 Ishihara plates), and a relative afferent pupillary defect in the left eye. Initial fundus exam of that eye revealed optic disc edema with nasal hemorrhages as well as peripapillary macular edema. There was a central scotoma with nasal steps on the Humphrey visual field (mean deviation -13.24 dB). Fluorescein angiography demonstrated disc leakage with inferior arcuate hypoperfusion. Optical coherence tomography (OCT) showed subsequent intraretinal exudates in the nasal macula bilaterally, worse in the left eye. Infectious workup and neuro-imaging were unremarkable. The patient was treated with intravenous methylprednisolone (IVMP) pulse and intravenous immunoglobulin (IVIG) at initial hospitalization, followed by a slow oral prednisone taper along with monthly IVIG outpatient. Her visual acuity in the left eye improved to 20\/20 at 6-month follow-up visit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and importance<\/jats:title>\n                    <jats:p>ICI-associated neuroretinitis is rare but vision-threatening and may emerge or worsen during systemic corticosteroid tapering for concurrent irAEs. Prompt recognition, exclusion of infectious mimics, and multidisciplinary management can yield meaningful visual recovery. Comprehensive neuro-ophthalmic assessment for ICI-associated neuro-ophthalmic complications including evaluation of color vision and pupillary function, documentation of fundus appearance, and additional ancillary testing with visual field and OCT analysis is essential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1872343","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T08:38:26Z","timestamp":1788424706000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Neuroretinitis following combination checkpoint inhibition therapy with nivolumab and ipilimumab for stage IIIC melanoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Nuha S.","family":"Arefin","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Dell Seton Medical Center at The University of Texas","place":["Austin, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Moon","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Dell Seton Medical Center at The University of Texas","place":["Austin, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron B.","family":"Roller","sequence":"additional","affiliation":[{"name":"Austin Retina Associates","place":["Austin, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moe H.","family":"Aung","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Dell Seton Medical Center at The University of Texas","place":["Austin, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000527","article-title":"Neuroretinitis: a review","volume":"29","author":"Abdelhakim","year":"2018","journal-title":"Curr Opin Ophthalmol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2147\/EB.S277760","article-title":"Neuro-ophthalmic complications of immune checkpoint inhibitors: a systematic review","volume":"12","author":"Yu","year":"2020","journal-title":"Eye Brain"},{"key":"B3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2024.12.028","article-title":"Pathogenic mechanisms of immune checkpoint inhibitor (ICI)-associated retinal and choroidal adverse reactions","volume":"272","author":"Haliyur","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12348-016-0082-3","article-title":"Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma","volume":"6","author":"Hahn","year":"2016","journal-title":"J Ophthalmic Inflammation Infect"},{"key":"B5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00091","article-title":"Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis","volume":"10","author":"Almutairi","year":"2020","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.05.003","article-title":"Immune checkpoint inhibitor-associated optic neuritis","volume":"127","author":"Francis","year":"2020","journal-title":"Ophthalmology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11174993","article-title":"Ocular inflammation induced by immune checkpoint inhibitors","volume":"11","author":"Chaudot","year":"2022","journal-title":"J Clin Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02258.x","article-title":"Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin","volume":"15","author":"Tselis","year":"2008","journal-title":"Eur J Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3129\/i09-238","article-title":"Intravenous immunoglobulin in recurrent-relapsing inflammatory optic neuropathy","volume":"45","author":"Stiebel-Kalish","year":"2010","journal-title":"Can J Ophthalmol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1474-4422(22)00187-9","article-title":"Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment","volume":"22","author":"Bennett","year":"2023","journal-title":"Lancet Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000138437.99046.6b","article-title":"Plasma exchange for severe optic neuritis: treatment of 10 patients","volume":"63","author":"Ruprecht","year":"2004","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8073-8","article-title":"Plasma exchange response in 34 patients with severe optic neuritis","volume":"263","author":"Deschamps","year":"2016","journal-title":"J Neurol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1872343\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T08:38:26Z","timestamp":1788424706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1872343\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":14,"alternative-id":["10.3389\/fonc.2026.1872343"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1872343","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1872343"}}